^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
Excerpt:
...The tumor harbors epidermal growth factor receptor (EGFR) mutations(include 19del, L858R, T790M, G719X, L861Q, S768I, 20 A763-Y764ins), and at least concurrent with TP53 6....
Trial ID:
Source:
Title:
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations
Published date:
04/05/2023
Excerpt:
A total of 52 Chinese patients were enrolled, of whom 17 harbored EGFR 19 del and 35 harbored EGFR L858R mutation. The objective response rate (ORR) was 75.0% and the disease control rate (DCR) was 96.2%; the mPFS was 17.0 months (95% CI: 11.46-22.54), while the mOS was not reached....Osimertinib combined with bevacizumab shows promising results in EGFR-mutated NSCLC patients with brain metastasis, and the side effects are tolerable.
DOI:
10.1111/1759-7714.14880
Trial ID:
Source:
Title:
VP3_2021 - A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Published date:
09/13/2021
Excerpt:
...combined Osi/Bev versus Osi in pts with NSCLC with EGFR-mt (exon 19 del or L858R) and T790M-mt at progression on prior EGFR TKI...the median PFS was 15.4m (95% CI 9.2-18.0) and 12.3m (6.2-17.2) (PFS events: 64 & 65) in the Osi/Bev and Osi arm respectively (HR 0.96; 0.68- 1.37; p=0.83). Median OS was 24.0m (17.8-32.1) in Osi/Bev and 24.3m (16.9-37.0) in Osi arm (deaths: 46 & 43) (HR 1.03; 0.67-1.56; p=0.91). ORR was 55% in both arms.
Trial ID:
Source:
Title:
Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report
Published date:
12/29/2022
Excerpt:
A 53-year-old woman, never smoked, was diagnosed with EGFR-mutant (exon 19 deletion, diagnosis method: ADx-ARMs) NSCLC with asymptomatic solitary brain metastasis on March 15, 2014, merely 1 month after lung cancer surgery...The novelty of our case is prolonged use of osimertinib in combination with the 4th line bevacizumab that achieved a longer survival.
DOI:
10.21037/tcr-22-1671
